Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients

Advances in Therapy

Volumn 25, Issue 3, 2008, Pages 266-273

  Moraloglu, Ozlem ^a   Kilic, Sevtap ^a,b   Karayalçin, Rana ^a   Yuksel, Beril ^a   Tasdemir, Nicel ^a   Işik, Ayça ^a   Ugur, Mustafa ^a  

^a Zekai Tahir Burak Women's Health and Education Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

GnRH agonists; GnRH antagonists; IVF outcome

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; DESOGESTREL; DESOLETT; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROSTAGLANDIN E2; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; ECHOGRAPHY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; TURKEY (REPUBLIC);

EID: 59249091013     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0028-8     Document Type: Article

References (24)

1. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of the embryos after in vitro fertilization. N Engl J Med. 1998;339:573-577.
2. Albano C, Smitz J, Camus M, et al. Hormonal profile during the follicular phase in cycles stimulated with recombination of human menopausal gonadotropin and gonadotropin-releasing hormone antagonist (Cetrorelix). Hum Reprod. 1996;11:14-18.
3. Rivier JE, Porter J, Rivier CL. New effective GnRH antagonists with minimal potency for histamine release in vitro. J Med Chem. 1986;29:1846-1851.
4. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;(3):CD001750.
5. Hohmann FP, Macklon NS, Fauser BCJM. A randomized comparison of two ovarian stimulation protocols with GnRH antagonist cotreatment for IVF commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRHa protocol. J Clin Endocrinol Metab. 2003;88:166-173.
6. Kolibianakis EM, Albano C, Kahn J, Camus M. Exposure to high levels of luteinizing hormone and estradiol in early follicular phase of GnRH antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79:603-607.
7. Ludwig M, Katalinic A, Banz C. Tailoring the GnRH antagonist cetrorelix acetate to individual patient's needs in ovarian stimulation for IVF: results of prospective, randomized study. Hum Reprod. 2002;17:2842-2845.
8. Mansour RT, Aboulghar MA, Serour GI. The use of clomiphene citrate/human menopausal gonodotropins in conjunction with GnRH antagonist in an IVF/ ICSI program is not a cost effective protocol. Acta Obstet Gynecol Scand. 2003;82:48-52.
9. Hwang J-L, Huang L-W, Hsieh B-C. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod. 2003;18:45-49.
10. Del Gadillo JCB, Siebzehnrübl E, Dittrich R. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: A matched study. Eur J Obstet Gynecol Reprod Biol. 2002;102:179-183.
11. Ragni G, Vegetti W, Baroni E. Comparison of luteal phase profile in gonadotropin stimulated cycles with or without a gonadotropin-releasing hormone antagonist. Hum Reprod. 2001;16:2258-2262.
12. Practice Committee of the Society for Assisted Reproductive Technology; Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril. 2006;86(5 suppl):51-52.
13. Londra L, Inza R, Lombardi E, Marconi G, Young E, Kenny A. GnRh antagonist versus GnRh agonist in good prognosis IVF patients. Hum Reprod. 2003;18(suppl 1):114.
14. Borm G, Mannaerts B, for the European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Hum Reprod. 2000;15:1490-1498.
15. Olivennes F, Belaisch-Allart J, Emperaire JC. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314-320.
16. Fluker M, Grifo J, Leader A, Levy M, for the North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38-45.
17. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644-651.
18. Bahceci M, Ulug U, Ben-Shlomo I. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: A randomized, prospective, pilot study. J Reprod Med. 2005;50:84-90.
19. Zikopoulos K, Kapanis A, Adonakis G. A prospective randomized study comparing gonadotropin releasing hormone agonists or gonadotropin releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia Fertil Steril. 2005;83:1354-1362.
20. Check ML, Check JH, Choel JK. Effect of antagonists versus agonists on in vitro fertilization outcome. Clin Exp Obstet Gynecol. 2004;31:257-259.
21. Causio F, Sarcina E, Leonetti T. GnRH agonist versus GnRH antagonist in an IVF programme: Luteal phase hormonal characteristics. Hum Reprod. 2004;19:i103.
22. Albano C, Felberbaum RE, Smitz J. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod. 2000;15:526-531.
23. Badrawy A, Al-Inany H, Hussein M, Zaki S, Ramzy AM. Agonist versus antagonist in ICSI cycles: A randomized trial and cost effectiveness analysis. Middle East Fertil Soc J. 2005;10:49-54.
24. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril. 2005;83:1700-1707.